Genoway

Genoway Operating Expenses

The Total Operating Expenses of Genoway (ALGEN.PA) as of Oct 11, 2026 is 19.66 M EUR. In the previous year, Total Operating Expenses was 17.03 M EUR — a change of 15.38% (higher).

Operating Expenses

19.66 MEUR

YoY

15.38%

Last updated:

Total Operating Expenses of Genoway is 2024 19.66 M EUR. Total Operating Expenses of Genoway was 2023 17.03 M EUR. It decreases by 15.38% higher compared to the previous year.

The Genoway Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2017
5.21 M EUR
Jan 1, 2018
6.38 M EUR
Jan 1, 2019
11.33 M EUR
Jan 1, 2020
12.88 M EUR
Jan 1, 2021
14.57 M EUR
Jan 1, 2022
15.13 M EUR
Jan 1, 2023
17.03 M EUR
Jan 1, 2024
19.66 M EUR
The Genoway Operating Expenses history
YEAROperating ExpensesYoY
19.66 MEUR+15.38%
17.03 MEUR+12.58%
15.13 MEUR+3.88%
14.57 MEUR+13.06%
12.88 MEUR+13.75%
11.33 MEUR+77.39%
6.38 MEUR+22.48%
5.21 MEUR-42.25%
9.03 MEUR+106.83%
4.36 MEUR+3.44%
4.22 MEUR—
Access this data via the Eulerpool API

Genoway Stock analysis

What does Genoway do? Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies. The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression. Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo. Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry. Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells. In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues. Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs. Genoway is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genoway stock

Total Operating Expenses of Genoway is 19.66 M EUR in 2024.

Total Operating Expenses of Genoway changed from 17.03 M EUR to 19.66 M EUR, representing a 15.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Genoway since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Genoway historically and in real time.

Access this data via the Eulerpool API

Income Statement — Genoway

All Key Metrics — Genoway